lornoxicam Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Lornoxicam, also known as chlortenoxicam, is a nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. It is available in oral and parenteral formulations.   Wikipedia

Chemistry

  • SMILES: CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O
  • InChIKey: WLHQHAUOOXYABV-UHFFFAOYSA-N
  • Mol. Mass: 371.83
  • ALogP: 2.3
  • ChEMBL Molecule:
    lornoxicam  
More Chemistry

Pharmacology

Alternative names

2h-thieno(2,3-e)-1,2-thiazine-3-carboxamide, 6-chloro-4-hydroxy-2-methyl-n-2-pyridinyl-, 1,1-dioxide | chlortenoxicam | ctx | lorcam | lornoxicam | lornoxicamum | ro-139297 | xefo | xefocam

Organizations (32)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (14)

Approved Indications (1)


 

Pain

Experimental Indications - Clinical Trial Phases 1-4 (14)


 

Acute Coronary Syndrome (Phase 4)

Alzheimer Disease (Phase 2)

BCG Vaccine (Phase 4)

Bunion (Phase 2)

Drug Delivery Systems (Phase 4)

Fractures, Bone (Phase 1/Phase 2)

Headache ()

Hematopoietic Stem Cell Transplantation (Phase 4)

Hernia, Inguinal (Phase 3)

Migraine Disorders (Phase 2)

Orthopedic Procedures (Phase 2)

Pain (Phase 2)

Pain, Postoperative (Phase 4)

Urinary Bladder Neoplasms (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 14
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue